After years of integrating health equity into value-based care, recent federal policy changes are reshaping how disparities are measured, reported, and addressed across the US health system.
After years of integrating health equity into value-based care, recent federal policy changes are reshaping how disparities are measured, reported, and addressed across the US health system.
The 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), to be held September 5-6 in Boston, will confront these challenges head-on through 13 powerful abstracts that demonstrate what it takes to translate evidence into...
The 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), to be held September 5-6 in Boston, will confront these challenges head-on through 13 powerful abstracts that demonstrate what it takes to translate evidence into...
Johnson & Johnson’s research highlights the significant impact of the FDA’s Accelerated Approval Program, estimating that earlier access to cancer therapies has provided approximately 263 000 additional life years to patients, reinforcing the...
Johnson & Johnson’s research highlights the significant impact of the FDA’s Accelerated Approval Program, estimating that earlier access to cancer therapies has provided approximately 263 000 additional life years to patients, reinforcing the...
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Tom Valuck, MD, JD; Erik Muther; Theresa Schmidt, MA, PMP, CSPO; Danny Bellet, MBA; Donna Dugan, PhD, MS; David Sloan, PhD
This past fall, leaders from the Real Chemistry Market Access team attended key quality-related events to understand trends and learn from other quality and value experts.
This past fall, leaders from the Real Chemistry Market Access team attended key quality-related events to understand trends and learn from other quality and value experts.
Tom Valuck, MD, JD; Anne DiSalvo, MPH, MBA; Kendall Logan, MPH; Erik Muther
This is the second part of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, the racial and ethnic disparities in HPV vaccination are explored.
This is the second part of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, the racial and ethnic disparities in HPV vaccination are explored.
Tom Valuck, MD, JD; Anne DiSalvo, MPH, MBA; Kendall Logan, MPH; Erik Muther
This is the first of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, vaccination disparities are explored among the highest and lowest performing states.
This is the first of a 3-part blog series that explores issues related to HPV vaccination rates in the US. In this blog, vaccination disparities are explored among the highest and lowest performing states.
We previously wrote about lessons from the Oncology Care Model (OCM) that the Center for Medicare and Medicaid Innovation (CMMI) could apply to the Enhancing Oncology Model (EOM). Subsequently, CMMI recently released an evaluation report for...
We previously wrote about lessons from the Oncology Care Model (OCM) that the Center for Medicare and Medicaid Innovation (CMMI) could apply to the Enhancing Oncology Model (EOM). Subsequently, CMMI recently released an evaluation report for...
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...